Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Alkermes PLC. (ALKS)
A forensic read on Alkermes PLC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
16.0
Distress distance
Clean
Earnings quality
4
Forensic signals
125.5
P / E (ttm)
13.3%
ROE
$8.3B
Market cap
-5.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Alkermes PLC. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 16.0, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
353d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 275 to 353 FY2024→FY2025 (against cost of goods sold; inventory +8% vs -20% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
+1.0%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +3% over the last 3 years to FY2025 (+1.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~3%.
+19.7%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +19.7% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 21% of net operating assets, diverging from the balance-sheet accrual read.
13.5%
FY2025
Return on invested capital.Return on invested capital is 13.5% in the latest fiscal year and rising from -0% — a modest positive spread over its ~10% cost of capital — growth adds value, though not dramatically.
Key fundamentals
Latest Revenue$1.48B
Revenue Growth YoY-5.2%
Revenue CAGR (3yr)+9.9%
Net Margin16.4%
Free Cash Flow$480.3M
Return on Equity13.3%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Alkermes PLC.'s actual 10-K/10-Q/8-K filings?